Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Gemtuzumab Ozogamicin in AML and High-Risk MDS
NCT00968071Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2008
- Primary completion
- Aug 2012
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine and gemtuzumab ozogamicin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Complete Response at 36 weeks. Started Feb 2008; status: completed.
02
Drugs
decitabinegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00968071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00968071.